Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV000995456 | SCV001149630 | uncertain significance | not provided | 2016-06-01 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002489494 | SCV002788556 | uncertain significance | Epilepsy, childhood absence, susceptibility to, 6; Hyperaldosteronism, familial, type IV | 2022-01-10 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003769341 | SCV004571827 | uncertain significance | Idiopathic generalized epilepsy; Hyperaldosteronism, familial, type IV | 2023-03-27 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CACNA1H protein function. ClinVar contains an entry for this variant (Variation ID: 807340). This variant has not been reported in the literature in individuals affected with CACNA1H-related conditions. This variant is present in population databases (rs369356684, gnomAD 0.006%). This sequence change replaces threonine, which is neutral and polar, with serine, which is neutral and polar, at codon 822 of the CACNA1H protein (p.Thr822Ser). |
Ambry Genetics | RCV004030195 | SCV004915135 | uncertain significance | Inborn genetic diseases | 2023-09-22 | criteria provided, single submitter | clinical testing | The c.2465C>G (p.T822S) alteration is located in exon 11 (coding exon 10) of the CACNA1H gene. This alteration results from a C to G substitution at nucleotide position 2465, causing the threonine (T) at amino acid position 822 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |